Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NASDAQ | Common Stock
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.
The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX.
The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform.
It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA.
The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005.
Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.58 Increased by +21.62% | -0.75 Increased by +22.67% |
| Feb 28, 24 | -0.62 Increased by +34.74% | -0.72 Increased by +13.89% |
| Nov 8, 23 | -1.63 Decreased by -39.32% | -0.85 Decreased by -91.76% |
| Aug 8, 23 | -0.80 Increased by +9.09% | -0.78 Decreased by -2.56% |
| May 9, 23 | -0.74 Increased by +21.28% | -0.70 Decreased by -5.71% |
| Feb 28, 23 | -0.95 Decreased by -2.15% | -0.95 |
| Nov 8, 22 | -1.17 Decreased by -6.36% | -0.89 Decreased by -31.46% |
| Aug 9, 22 | -0.88 Increased by +17.76% | -0.86 Decreased by -2.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 56.78 M Increased by +95.68% | -141.18 M Decreased by -66.69% | Decreased by -248.65% Increased by +14.81% |
| Jun 30, 23 | 58.13 M Increased by +104.93% | -67.32 M Decreased by -9.47% | Decreased by -115.80% Increased by +46.58% |
| Mar 31, 23 | 49.33 M Increased by +95.29% | -66.05 M Decreased by -2.59% | Decreased by -133.89% Increased by +47.47% |
| Dec 31, 22 | 49.92 M Increased by +92.37% | -144.55 M Decreased by -129.09% | Decreased by -289.56% Decreased by -19.09% |
| Sep 30, 22 | 29.02 M Increased by +46.95% | -84.69 M Decreased by -13.87% | Decreased by -291.89% Increased by +22.51% |
| Jun 30, 22 | 28.37 M Increased by +50.86% | -61.50 M Increased by +14.82% | Decreased by -216.78% Increased by +43.54% |
| Mar 31, 22 | 25.26 M Increased by +89.95% | -64.39 M Increased by +10.12% | Decreased by -254.88% Increased by +52.68% |
| Dec 31, 21 | 25.95 M Increased by +133.09% | -63.10 M Increased by +19.42% | Decreased by -243.15% Increased by +65.43% |